Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...
Pharmaceutical Technology on MSN6d
Novo Nordisk secures FDA approval for Ozempic in diabetes with CKDThe new indication makes Ozempic the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available for people with T2D ...
Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...
People who have been using Ozempic have been complaining of a bizarre side-effect, which has been nicknamed 'Ozempic butt'.
Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback